AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01495754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: coffee
Description: Comparison of different amounts of coffee
Study NCT02005484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4 mg/kg initial dose, followed by 2 mg/kg
Study NCT01844362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine transplantation
Description: Transplantation of the uterus from live donor and IVF treatment.
Study NCT01621087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safflower oil
Description: Liquid safflower oil and safflower oil polyunsaturated margarine
Study NCT03034772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorzolamide-timolol
Description: Topical eye drop (active comparator) used twice daily for study duration
Study NCT03034772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: Topical eye drop (placebo comparator) used twice daily for study duration
Study NCT03933735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNB-383B
Description: Intravenous (IV) Injection
Study NCT03026426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONEMO
Description: Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists.
Study NCT02043002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET scan
Study NCT04740762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The women in the intervention groups were administered a three-session intervention program in addition to the routine care they received.The program encompassed providing the women with an educational booklet, childbirth stories and childbirth videos that were created to reduce their fears of childbirth.The interviews were held a total of three times, in gestational weeks 28-30, 31-33 and 34-36. The duration of the intervention at each visit was 60-80 minutes. Depending on the woman's own preference, she was invited to visit the delivery room at the second or last session and meet the midwives there. The women who did not wish to go to the delivery room were alternatively provided with photographs of the delivery room so they could take a look. Again as part of the education program, the women were given the links to the selected childbirth videos and given the opportunity to watch them.
Study NCT01445366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High volume post dilution hemodiafiltration
Description: The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
Study NCT01445366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flux hemodialysis
Description: The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
Study NCT03194724 — intervention group
Intervention type: OTHER
Intervention: Vitamin A supplementation
Description: Bi annual vitamin A supplementation programme
Study NCT03741530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide Tablets
Description: Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
Study NCT03741530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard management for ICH
Description: Usual care and drug in hospital
Study NCT03741530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard management for ICH
Description: Usual care and drug in hospital
Study NCT03628872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis.
Study NCT03628872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis.
Study NCT03628872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser
Description: This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
Study NCT03628872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand instruments
Description: 11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
Study NCT05005923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgically performed scaling and root planing
Description: Treatment of patients with periodontitis was performed using manual and ultrasonic instruments.
Study NCT01102881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose polymer fiber
Description: 20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
Study NCT01102881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber made from corn starch
Description: 20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
Study NCT01102881 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: low fiber breakfast cereal and muffin
Study NCT04246281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to the nerves in your low back. The SPRINT System includes up to two leads (small wires) that are placed through your skin into your low back. The leads attach to devices worn on your body that deliver stimulation (called Stimulators).
Study NCT04246281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard interventional management of low back pain
Description: Your doctor will determine which procedure or intervention is appropriate for your back pain. You may receive radiofrequency ablation, spinal cord stimulation, surgery, or another procedure or treatment, as appropriate.
Study NCT03447015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ambulation
Description: Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking).
Study NCT01796899 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brivaracetam 10 mg oral tablet
Study NCT01796899 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brivaracetam 50 mg oral tablet
Study NCT03142737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red kidney bean intake
Description: Each participant will consume 1/2 cup of cooked red kidney bean
Study NCT03142737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs intake
Description: Each participant will consume 2 cooked large eggs.
Study NCT03142737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanut butter intake
Description: Each participant will consume 2 tablespoons of peanut butter.
Study NCT03142737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground beef intake
Description: Each participant will consume 2 ounces of 90% lean ground beef.
Study NCT03142737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intact beef intake
Description: Each participant will consume 2 ounces of intact beef.
Study NCT03098160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evofosfamide
Description: Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
Study NCT03098160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
Study NCT02440464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
Study NCT02440464 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Allogeneic HSCT
Description: Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
Study NCT02440464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
Study NCT02440464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fludarabine
Description: Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
Study NCT02440464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
Study NCT02440464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melphalan
Description: Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
Study NCT02440464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
Study NCT02440464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
Study NCT02440464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
Study NCT02440464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
Study NCT01796899 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brivaracetam 75 mg oral tablet
Study NCT01796899 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brivaracetam 100 mg oral tablet
Study NCT01796899 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)
Study NCT03925675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT with F-Fluciclovine (Axumin)
Description: Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 50 mcg/kg for reversal of residual neuromuscular blockade
Study NCT02327923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: 10 mcg/kg with neostigmine
Study NCT01527188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100IR
Description: 100IR sublingual tablet of
Study NCT01527188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 300IR
Description: 300IR sublingual tablets of
Study NCT01527188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 500IR
Description: 500IR sublingual tablet of
Study NCT01527188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sublingual tablet of
Study NCT03678155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain app
Description: Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
Study NCT03678155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pain app
Description: Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
Study NCT02829593 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hypoglycemia (low blood sugar) and MRI
Description: hypoglycemia (low blood sugar) and MRI
Study NCT02829593 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypoglycemia (low blood sugar) and MRI
Description: hypoglycemia (low blood sugar) and MRI
Study NCT02310139 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Study NCT03489395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
Study NCT02188238 — intervention group
Intervention type: OTHER
Intervention: Saliva Sample Collection
Description: Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
Study NCT01120431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral rehydration fluid
Description: Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
Study NCT01120431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic hydration fluid and recombinant human hyaluronidase
Description: Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
Study NCT00854581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Administered subcutaneously.
Study NCT02077868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Maintenance
Description: Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
Study NCT02077868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703 treatment
Description: MGN1703 will be used as single agent maintenance treatment
Study NCT02730832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires completed at D0
Study NCT00854581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Description: Administered intravenously.
Study NCT00854581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Administered orally.
Study NCT00854581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
Study NCT02242357 — intervention group
Intervention type: DRUG
Intervention: Micardis®
Study NCT02242357 — intervention group
Intervention type: DRUG
Intervention: Micardis® Plus
Study NCT04106310 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux dialyzer
Description: a dialyzer meeting the definition of high-flux
Study NCT02053636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lucitanib
Study NCT02730832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires completed at D15 (test-retest for 30 patients)
Study NCT04731740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: PO
Study NCT04731740 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV
Study NCT04731740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Investigators' choice
Study NCT04329156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digitally Flip Technique
Description: A prefabricated shell will be made then after implant placement, the shell will be attached to a plastic abutment using flowable composite to make a customized healing abutment.
Study NCT04329156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stock Healing Abutment
Description: After implant placement, a stock healing abutment will be placed onto the implant and screwed on. It will be selected to be 1-2 mm above the gingival margin and slightly smaller in diameter than the intended final restoration.
Study NCT03737357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLActive® implant
Description: One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
Study NCT03737357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLA® implant
Description: One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
Study NCT02184988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum purified neurotoxin, Type A
Description: The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
Study NCT04233255 — intervention group
Intervention type: DEVICE
Intervention: Neuromuscular Ultrasound (US)
Description: Quantitative ultrasound measurements will be performed to studied muscles according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.The study will be performed using My lab 7 ultrasound system (Esaote company, Italy) that is equipped by 7-19 MHz linear array transducer and color and power Doppler.~Technique: evaluation of studied muscles for echo intensity (ECHO), quantitative assessments of echointensity, muscle perfusion, transverse and longitudinal sections of the muscle and its thickness at rest and during maximal voluntary contractions (MVC), overlying subcutaneous fat, cross-sectional area (CSA), and angled fibers of pennate muscles.
Study NCT04233255 — intervention group
Intervention type: DEVICE
Intervention: Electrophysiological studies
Description: Includes: Motor and sensory nerve conduction study, F-wave and H-reflex study to assess the proximal roots, Electromyography (EMG) of the studied muscles.~using machine: recordings will be performed with a Nihon Kohden equipment (model 7102) with the following parameters: sweep time 8 ms/D, sensitivity 0.5 mV/D, low frequency filter 2 Hz, high frequency filter 10 kHz, stimulation duration 0.1 ms and stimulation frequency 1 Hz.